AI Article Synopsis

  • Langer-Giedion syndrome (LGS) results from a deletion in the 8q23q24 region, leading to symptoms like bony growths, facial and skeletal deformities, and sometimes intellectual disabilities.
  • Researchers analyzed two unrelated patients with these deletions, identifying a critical 3.2-Mb region linked to typical LGS features and emphasizing the roles of several key genes.
  • This study adds to the understanding of LGS by helping to establish better genotype-phenotype correlations, which are currently lacking in existing research.

Article Abstract

Langer-Giedion syndrome (LGS) is caused by a contiguous deletion at 8q23q24, characterized by exostoses, facial, ectodermal, and skeletal anomalies, and, occasionally, intellectual disability. LGS patients have been diagnosed clinically or by routine cytogenetic techniques, hampering the definition of an accurate genotype-phenotype correlation for the syndrome. We report two unrelated patients with 8q23q24 deletions, characterized by cytogenomic techniques, with one of them, to our knowledge, carrying the smallest deletion reported in classic LGS cases. We assessed the pathogenicity of the deletion of genes within the 8q23q24 region and reviewed other molecularly confirmed cases from the literature. Our findings suggest a 3.2-Mb critical region for a typical presentation of the syndrome, emphasizing the contribution of the TRPS1, RAD21, and EXT1 genes' haploinsufficiency, and facial dysmorphisms as well as bone anomalies as the most frequent features among patients with LGS. We also suggest a possible role for the CSMD3 gene, whose deletion seems to contribute to central nervous system anomalies. Since studies performing such correlation for LGS patients are limited, our data contribute to improving the ge-notype-phenotype characterization for LGS patients.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000522034DOI Listing

Publication Analysis

Top Keywords

lgs patients
12
critical region
8
typical presentation
8
langer-giedion syndrome
8
lgs
6
patients
5
minimal critical
4
region genes
4
genes typical
4
presentation langer-giedion
4

Similar Publications

Prognostic Value of Response Evaluation Using PSMA PET/CT in Patients with Metastatic Prostate Cancer (RECIP 1.0): A Systematic Review and Meta-analysis.

Acad Radiol

January 2025

University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network-Sinai Health System -Women's College Hospital, University of Toronto, Toronto, ON, Canada (S.A.M., P.V.H., U.M., A.B.D.). Electronic address:

Rationale And Objectives: Recently, the Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) was proposed to better evaluate treatment response in prostate cancer patients using PET/CT with prostate-specific membrane antigen (PSMA) than more traditional approaches like metabolic PET evaluation response criteria in solid tumor (PERCIST 1.0).

View Article and Find Full Text PDF

Objective: Controversy exists regarding treatment of symptomatic low-grade spondylolisthesis (LGS). Both one- and two-stage fusions are commonly performed, but it is unclear if one approach is superior. We aim to compare the satisfaction rates and patient-reported outcomes (PROs) in patients with LGS undergoing one- versus two-stage lumbar spine surgery.

View Article and Find Full Text PDF

Lossless and reference-free compression of FASTQ/A files using GeneSqueeze.

Sci Rep

January 2025

Rajant Health Incorporated, 200 Chesterfield Parkway, Malvern, PA, 19355PA, USA.

As sequencing becomes more accessible, there is an acute need for novel compression methods to efficiently store sequencing files. Omics analytics can leverage sequencing technologies to enhance biomedical research and individualize patient care, but sequencing files demand immense storage capabilities, particularly when sequencing is utilized for longitudinal studies. Addressing the storage challenges posed by these technologies is crucial for omics analytics to achieve their full potential.

View Article and Find Full Text PDF

Serum miR-365b-5p/miR-222-5p as a potential diagnostic biomarker for long-term weight loss in patients with morbid obesity after bariatric surgery.

Metabolism

December 2024

Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Malaga, Spain; Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen de la Victoria, Malaga, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto Salud Carlos III, Madrid, Spain.

Background: The successful weight loss following bariatric surgery is not achieved in all patients with morbid obesity (MO). This study aims to determine whether a serum miRNA profile can predict this outcome.

Design: Thirty-three patients with MO were classified in "Good Responders" (GR, percentage of excess weight loss (%EWL) ≥ 50 %) or "Non-Responders" (NR, %EWL < 50 %) according to the %EWL 5-8 year following bariatric surgery.

View Article and Find Full Text PDF
Article Synopsis
  • Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS) are severe epilepsy types often seen in young children, and a CBD medication (Epidyolex®) has been reimbursed in the Netherlands since December 2022 to help treat their seizures.
  • A cost-effectiveness analysis using a Markov model showed that using CBD along with usual care for LGS resulted in additional costs of €28,338 but provided increased quality-adjusted life-years (QALYs) of 1.318, making it cost-effective below the €80,000 threshold.
  • For DS patients, CBD plus usual care showed a cost saving of €23,642 while increasing QAL
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!